[go: up one dir, main page]

UA111566C2 - Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate - Google Patents

Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate

Info

Publication number
UA111566C2
UA111566C2 UAA201506803A UAA201506803A UA111566C2 UA 111566 C2 UA111566 C2 UA 111566C2 UA A201506803 A UAA201506803 A UA A201506803A UA A201506803 A UAA201506803 A UA A201506803A UA 111566 C2 UA111566 C2 UA 111566C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
extended release
active ingredient
triasol
morpholinium
Prior art date
Application number
UAA201506803A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ірина Віталіївна Сапсай
Олена Миколаївна Глуменко
Жанна Миколаївна Кравчук
Сергій Олегович Шведський
Original Assignee
Публічне Акціонерне Товариство "Київмедпрепарат"
Публічне Акціонерне Товариство "Галичфарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Публічне Акціонерне Товариство "Київмедпрепарат", Публічне Акціонерне Товариство "Галичфарм" filed Critical Публічне Акціонерне Товариство "Київмедпрепарат"
Priority to UAA201506803A priority Critical patent/UA111566C2/en
Publication of UA111566C2 publication Critical patent/UA111566C2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the pharmaceutical composition of extended release containing the active ingredient and at least one matrix-forming polymer agent selected from polyethylene oxide with molecular weight in the range of 100,000 to 10,000,000 Daltons and hydroxypropyl methylcellulose with nominal viscosity in the range of 3 to 100,000 mPa • s, in combination with one or more pharmaceutically acceptable excipients, and the active ingredient represents morpholine salt of thionitric acid with particle size less than 500 microns, and the active ingredient and matrix-forming polymer agent contained at a 1:0.2-1.9 ratio.
UAA201506803A 2015-07-09 2015-07-09 Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate UA111566C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA201506803A UA111566C2 (en) 2015-07-09 2015-07-09 Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA201506803A UA111566C2 (en) 2015-07-09 2015-07-09 Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate

Publications (1)

Publication Number Publication Date
UA111566C2 true UA111566C2 (en) 2016-05-10

Family

ID=56291987

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201506803A UA111566C2 (en) 2015-07-09 2015-07-09 Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate

Country Status (1)

Country Link
UA (1) UA111566C2 (en)

Similar Documents

Publication Publication Date Title
MX2015016112A (en) Tamper-resistant dosage form containing one or more particles.
MX2014011815A (en) Immediate release pharmaceutical compositions with abuse deterrent properties.
MY161930A (en) Antipsychotic injectable depot composition
DOP2015000006A (en) ETANERCEPT FORMULATIONS SHOWING A MARKING REDUCTION OF THE AMOUNT OF SUBVISIBLE PARTICLES
MX2013001677A (en) Stable formulations of linaclotide.
MX2015000114A (en) Extended release, abuse deterrent pharmaceutical compositions.
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
NZ739674A (en) Liquid polymer delivery system for extended administration of drugs
WO2013112959A8 (en) Antifibrotic compounds and uses thereof
MX2018008868A (en) Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties.
GEP20217308B (en) Orodispersible dosage unit containing an estetrol component
MX370890B (en) Composition comprising salbutamol sulphate.
MX2022006940A (en) Pharmaceutical compositions comprising cabotegravir.
NZ727834A (en) Fast acting orally disintegrating film
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2016040814A3 (en) Disulfide polymers and methods of use
EA201991287A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS BASED ON TIKAGRELOR FOR ORAL USE
MX2021014830A (en) CONJUGATES OF <i>π</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS.
WO2018085495A3 (en) Dissolvable films and methods of their use
EP4374861A3 (en) A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
MX2018004445A (en) Colloidal particles for use in medicine.
UA111566C2 (en) Pharmaceutical composition of extended release of morpholinium [(5-methyl-1h-1,2,4-triasol-3-yl)thio]acetate
ZA202104704B (en) Pharmaceutical composition